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Case Presentation
This 66-year-old man was diagnosed as having Guillain-Barré
syndrome 32 years ago. Because of back pain from residual
"arachnoiditis." he began to take approximately 12 tablets of
Percodan® per day. Slight proteinuria and a blood urea nitrogen
of 25 mg/dl were discovered 17 years ago when he was hospital-
ized for treatment of a gastric ulcer. He was hospitalized 14 years
ago because of fatigue, anemia, and azotemia. The physical ex-
amination was unremarkable: blood pressure was 140/80mm Hg,
blood urea nitrogen was 60 mg, and serum creatinine was 6.2 mg/
dl. A gastric ulcer was demonstrated on an upper GI series but
had healed by repeat examination several weeks later. By this
time the patient's accumulated phenacetin intake was estimated
to be 5 to 7kg, and on the advice of his physician he discontinued
all further ingestion of phenacetin-containing analgesics. La-
minagrams revealed symmetrical kidneys measuring 11.5 to 12
cm in length. Retrograde pyelography revealed no evidence of
obstruction or papillary necrosis. Urine culture grew Pseudo-
monas aeruginosa, and a course of colistin therapy was given.
Serum creatinine concentration rose from the admission level of
6.2 mg to 10.2 mg, but fell to 7.7 mg/dl by the time of discharge.
The rise in serum creatinine occurred 5 to 7 days after the colistin
was discontinued.
Six months later, the patient was hospitalized for fever, chills,
and acute left flank pain due to obstruction from a presumed ne-
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crotic papilla. Retrograde pyelography revealed thick purulent
material coming from the left ureteral orifice, but a catheter
could not be passed into that ureter. The urine culture contained
abundant pseudomonas, and the patient was treated again with
colistin. Ten days following admission his temperature again
rose to l0l F, left costovertebral angle tenderness recurred, and
the serum creatinine rose to 12 mg/dl. Retrograde pyelography
then revealed no evidence of obstruction of the left ureter, but
the calyces on the left showed marked scarring. At discharge, the
serum creatinine was 12 mg/dl, the hemoglobin was 9 g/dl, and
the carbon dioxide content was IS mEq/liter. The only medica-
tions given were a sulfonamide and sodium citrate. The serum
creatinine fell to 6 mgldl over the next I to 2 months and was 4.6
mg/dl 6 months later.
Over the next 5 years, the patient experienced at least seven
episodes of recurrent pseudomonas urinary tract infection,
which required treatment with potentially nephrotoxic antibiot-
ics. Sulfonamides, ampicillin. gentamicin, nitrofurantoin, car-
benicillin, and tetracycline were administered in attempts to
eliminate recurring gross pyuria and hematuria and to relieve an-
noying urinary tract symptoms. Tetracycline proved to be the
most effective of these agents, but the dosage required to rid the
patient of symptoms (750 mg/day) resulted in gastrointestinal up-
set. A combination of nitrofurantoin and a sulfonamide pre-
vented severe dysuria, but did not eliminate other characteristic
symptoms. A representative urinalysis during the latter thera-
peutic regimen revealed I to 2 red blood cells (RBC) per high-
power field (HPF), white blood cells (WBC) too numerous to
count, and no casts; urine cultures contained 10 to 30,000 cob-
flies of a nonhemolytic streptococcus and 30 to 100,000 colonies
of pseudomonas per milliliter. Sterile urine cultures were ob-
tained on more than one occasion following antibiotic therapy.
The serum creatinine concentration often increased during epi-
sodes of infection but returned to a baseline level of approxi-
mately 6 mgidl after treatment. During this period, the patient
had one episode of severe acidosis, but with continuous alkali
treatment his plasma bicarbonate concentration increased to 20
mEq/liter and his symptoms disappeared. In the last year of this
5-year period, a representative urinalysis revealed: specific grav-
ity 1.010, albumin 2+, pH 6, Ito 2 RBC/HPF with no casts, and
70 to 100 WBC/HPF. During this interval, the patient also suf-
fered an acute lateral wall myocardial infarction from which he
made an uneventful recovery.
Approximately 8 years ago, the serum creatinine was 10 mg
and the BUN 100 mg/dI; 7 years ago, the serum creatinine was
11.4 mg/dl and a protein-restricted diet was instituted because of
mild uremic symptoms. Alkaline phosphatase was 6.5 Bodansky
units, calcium was 6.9, and phosphorus was 6.2 mg/dl. Six years
ago the patient began chronic hemodialysis.
Three years ago the patient received an HLA-identical kidney
transplant from his 68-year-old brother. Two episodes of acute
rejection occurred shortly after transplantation, but both epi-
sodes were reversed by high-dose intravenous steroid therapy.
The serum creatinine shortly after discharge was 1.5 mg/dl. His
present medications include 10 mg/day prednisone, 100 mg/day
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azathioprine, 60 mg of codeine three times per day, and I tabletl
day Percodan®. Current laboratory values include a BUN of 25
mg and a serum creatinine of 1.6 mg/dl; the urine culture is ster-
ile.
Discussion
DR. PRISCILLA KINCAID-SMITH (Professor of
Medicine, University of Melbourne): Analgesic ne-
phropathy is a "community habit" in Australia and
certain European countries. The practice of habitu-
al, excessive analgesic intake predominantly affects
women, however. This patient is a man, and be-
cause the male-to-female ratio is 1:4 or 1:5 in anal-
gesic nephropathy, one immediately wonders about
the reason for analgesic abuse in his case. The men
in our own studies have tended to be much more
abnormal in behavioral terms; for example, all the
men in our original study, carried out between 1959
and 1962 at the Royal Melbourne Hospital, had at
some time been hospitalized for psychiatric treat-
ment [1]. This patient took Percodan® for a genuine
chronic painful disorder, but his use of the drug in
excessive quantities suggests that it had become a
"habit."
In 1964, Percodan® contained in addition to
oxycodone: 224 mg of aspirin, 160 mg of phenace-
tin, and 32 mg of caffeine. I would emphasize that it
is a mistake to label this patient's condition phe-
nacetin nephritis" because he took this mixture of
different agents. Analgesic nephropathy, or renal
papillary necrosis as a result of analgesic abuse, has
been associated with a great variety of analgesic
compounds. In no single patient has it been attrib-
uted to phenacetin alone, although patients have
been described who have taken only aspirin [2] or
paracetamol (acetominophen) [3]. Singling out one
ingredient as dangerous has the unfortunate effect
of suggesting that the other ingredients are safe.
One might argue that because papillary necrosis has
occurred in patients taking only aspirin, the term
"aspirin nephritis," not "phenacetin nephritis,"
should be used. In my opinion, both designations
are incorrect. This question has been debated for
many years, but the dangers of compound analge-
sics as opposed to the hazards of preparations con-
taining single ingredients are now becoming very
clear as experimental data from animals and hu-
mans become available. In Australia in 1962, phe-
nacetin was withdrawn from most over-the-counter
analgesics, which then were advertised as Safe—
contains no phenacetin." Of the two remaining phe-
nacetin-containing analgesic compounds, phenace-
tin was withdrawn from one in 1967 and was re-
placed with salicylamide. Twelve years later, about
one-third of patients presenting with analgesic ne-
phropathy have taken only aspirin, salicylamide,
and caffeine—no phenacetin—yet these people
have clinical features identical to those in patients
who have taken aspirin, phenacetin, and caffeine
(APC) [4]. Despite a steady reduction in phenace-
tin-containing analgesics between 1962 and 1975,
and even though phenacetin has not been available
in common over-the-counter preparations in Aus-
tralia for 4 years, the number of new patients pres-
enting with clinical analgesic nephropathy, dying,
or requiring dialysis has not declined (Fig. I). This
experience may be helpful to countries like the
United States, where restriction of phenacetin cur-
rently is being contemplated. It also points out the
problem in labeling a disease phenacetin nephri-
tis" when no definite evidence indicates that phe-
nacetin alone can cause the renal lesion.
Animal experiments that have attempted to re-
produce the renal lesions seen in humans usually
have been negative when phenacetin is used on its
own. Huge doses of phenacetin, 3000 mg/kg, pro-
duce only minor changes in the renal papillae [5].
Aspirin alone in a dose of 500 mg/kg produces papil-
lary necrosis and secondary cortical lesions resem-
bling those in humans in 30% of experimental ani-
mals [5]. Aspirin together with phenacetin or para-
cetamol produces papillary necrosis and secondary
cortical changes in 60% to 80% of laboratory rats [5,
6]. All nonsteroid antiinflammatory agents tested,
including phenylbutazone, mefenamic acid, indo-
methacin, phenazone, and propoxyphene, have
produced papillary necrosis in rats [7]. Recent re-
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Fig. 1. Frequency of analgesic-abuse nephropa thy among neu'
patients entering chronic hemodialysis programs in Australia.
Frequency has not declined in recent years despite the reduced
availability of phenacetin-containing analgesics. (Data from Aus-
tralia Kidney Foundation Registry)
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Fig. 2. Pat ho genesis of papillary necrosis in analgesic abuse. Papillary necrosis due to reduced medullary blood flow probably initiates
the process that results in chronic interstitial nephritis. The analgesic mixtures implicated in this condition are probably concentrated in
the renal medulla and may share a common ability to inhibit prostaglandin synthesis. (Kindly supplied by R. S. Nanra)
ports from the United States stress the importance
of propoxyphene (Darvon®) and propoxyphene
APC (Darvon Compound®) as causative agents [8,
91.
The mechanism whereby analgesics produce re-
nal damage is still debated. Experimental work now
suggests that the lesions of chronic interstitial ne-
phritis, as shown schematically in Fig. 2, are sec-
ondary to renal papillary necrosis [10, 11], and pa-
thologists generally accept the association [12, 13].
The potential for causing papillary necrosis shared
by so many nonsteroid antiinflammatory agents
suggests that some common property, such as the
ability to inhibit prostaglandin synthesis, accounts
for their toxic effects on the renal medulla. Prosta-
glandins are thought to play an important role in
regulating medullary blood flow; if true, this physio-
logic alteration would provide a possible mecha-
nism through which all of these chemically different
agents might cause papillary necrosis. Anti-
inflammatory agents, particularly indomethacin,
markedly reduce medullary blood flow and inhibit
prostaglandin synthesis [14]. Early changes in the
papillae in experimental animals, if ischemic, could
result from this reduction in blood flow [6]. Later,
occlusive lesions develop in the vasa recta, and
these may cause actual necrosis in the papillae [6,
15].
To return to the patient under discussion: the
considerable elevation of the BUN and creatinine
concentrations, in the presence of slight and inter-
mittent proteinuria, is a characteristic of renal fail-
ure from primary tubular and interstitial disease and
suggests analgesic nephropathy in particular.
Peptic ulceration, a feature of this patient, fre-
quently precedes analgesic nephropathy, often pre-
dating renal symptoms by several years [lii. Peptic
ulceration is attributed to prolonged ingestion of
high-dose salicylates [16]. Although papillary ne-
crosis was not demonstrated on radiograms, the di-
agnosis of renal papillary necrosis cannot be ex-
cluded on this basis [1, 17]. In-situ lesions in which
necrotic papillae remain attached and hence do not
cause any of the characteristic radiologic features
are common [17].
This patient's recurrent episodes of pyelonephri-
tis are typical of the chronic relapsing course of an-
algesic nephropathy. Temporary failure of either
252 Nephrology Forum
Chronic
interstitial
nephritis
Medullary
calcification
Loop of Henle
—toxic damage
Renal papillary
necrosis
Vasa recta—medullary
ischem Ia
Maximum concentration of
- '4C-aspirin
- NAPA
Analgesic abuse and the kidney 253
kidney during acute infection, associated with ob-
struction by a necrotic papilla, is another character-
istic feature exhibited by this patient, as was his
moderate hypertension, which developed several
years after the onset of the pyelonephritis. Malig-
nant hypertension, however, can occur in patients
with this condition [4].
Five years of this patient's course were punc-
tuated by intermittent episodes of acute pyelone-
phritis caused by the same organism, namely
Pseudononas aeruginosa. It is very likely that this
organism was never eradicated and that the sterile
cultures, obtained after a course of colistin or gen-
tamicin, reflected a temporary clearing from the
urine, while the necrotic debris in the pelvis re-
mained infected. The organism that was present in
the urine 14 years ago was almost certainly acquired
in hospital, perhaps during retrograde urography.
Infection persisted until dialysis was started 8 years
later, and required repeated hospital admissions for
parenteral administration of potentially nephrotoxic
antibacterial agents. The infections and their treat-
ment probably contributed to this patient's gradual
progression to end-stage renal failure.
Fourteen years ago, this man's kidneys were only
slightly reduced in size. Because the serum creati-
nine concentration one year later was only 4.6 mg/
dl, it should have been possible with optimal man-
agement to restore his BUN and serum creatinine to
normal or nearly normal levels. This is a recover-
able form of renal failure and, in our experience,
patients almost invariably recover if factors such as
infection, hypertension, sodium depletion, and in-
termittent obstruction are promptly and effectively
corrected. The prognosis should be very good if the
patient's kidneys are normal or nearly normal in
size and if analgesic abuse ceases. In a study of 52
patients followed over a period of years, 50% im-
proved, 35% remained stable, and only 15% deteri-
orated [18].
One factor that may have led to a decline in renal
function in this man was the probable continued an-
algesic abuse. Although this is not fully docu-
mented, his reliance on Percodan® is strongly sug-
gested by continual attacks of acute papillary necro-
sis—manifested as macroscopic hematuria—as long
as 6 years after presentation. Such episodes usually
cease when analgesic abuse ceases, and I therefore
suspect that his analgesic abuse continued. Active
recurrent papillary necrosis aggravates urinary tract
infection, and both probably contributed to the pro-
gressive renal dysfunction in this patient. Because it
should be possible to eradicate pyuria in such pa-
tients by aggressive continuous treatment with ap-
propriate antibacterial agents, it is noteworthy that
this patient's pyuria persisted despite intermittent
treatment for the recurrent acute pseudomonas py-
elonephritis. The combination that might eradicate
pseudomonas infection consists of an initial course
of gentamicin or colistin followed by continuing
long-term treatment with a combination of oxytetra-
cycline and cotrimoxazole. These drugs can
achieve sufficiently high levels in the urine to sup-
press or even eradicate infection. In the patient un-
der consideration, a urine culture showed less than
1000 col/ml of pseudomonas on one occasion. Al-
though it was concluded that this urine was not in-
fected, the patient was undergoing sulfonamide
therapy at the time, and this might well have re-
duced the bacterial count. Counts as low as 200 coIl
ml can be shown to represent true persistent infec-
tion by needle aspiration of bladder urine, even
when patients are not currently receiving antibiotics
[19]. The low bacterial counts recorded in this man
probably represent true infection—not con-
tamination—because he had constant pyuria and re-
current episodes of active infection with the same
organism. The nitrofurantoin and sulfonamide that
he received on occasion may have produced low
bacterial counts in urine cultures, but these drugs
could not eradicate a pseudomonas infection. We
would never use nitrofurantoin in a patient with
such a high serum creatinine concentration because
peripheral neuritis could develop. The pyuria ap-
parently was eradicated only once following a
course of tetracycline, a drug that sometimes
achieves effective urine concentrations against
pseudomonas organisms.
The final factor that contributed to this patient's
irreversible progression to renal failure was the de-
velopment of glomerular lesions, manifested by al-
buminuria and hematuria 9 years ago. The develop-
ment of heavy proteinuria in a patient with analge-
sic nephropathy is a poor prognostic sign [4, 20].
Before heavy proteinuria develops, renal function
in such patients may intermittently improve or sta-
bilize; however, after the development of protein-
uria they tend to run a progressively downhill
course. The same is true in chronic atrophic pyelo-
nephritis and in reflux nephropathy [21, 22]. The
glomerular lesion in either disease is that of focal
and segmental hyalinosis or focal sclerosing glomer-
ulonephritis (Fig. 3). The primary form of this gb-
merular lesion usually is irreversible, as are the sec-
ondary lesions of analgesic nephropathy, reflux ne-
phropathy, and gouty nephropathy [23]. Once the
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Fig. 3. Focal sclerosing glomerulonephrit is in a patient u'ith analgesic-abuse nephropathy. The glomerular hyalinosis featured in this
photomicrograph occurs in a small percentage of patients with advanced analgesic-abuse nephropathy.
heavy proteinuria develops, one can confidently
predict progression to end-stage renal failure in I to
3 years, as occurred in this patient.
On at least one occasion, this patient was acidot-
ic. Severe acidosis, often out of proportion to the
BUN and serum creatinine concentrations, is a fea-
ture of renal failure due to analgesic nephropathy.
Even when renal function is only slightly impaired,
patients may have renal tubular acidosis [4].
Acute myocardial infarction is not unusual in a
man of this patient's years, but an inappropriately
high frequency of ischemic heart disease and other
complications of severe atheroma has been noted in
women, including premenopausal women, with an-
algesic nephropathy [24, 25]. We believe that ath-
eroma and its complications are unusually prevalent
in this group of patients. Myocardial infarction was
the cause of death in 25% of patients in our original
study [1].
This man reached end-stage renal failure requir-
ing dialysis 8 years after presentation; hence, he ran
a typical chronic course. A successful transplant
from an HLA-identical sibling was carried out after
bilateral nephrectomy, which I presume was per-
formed because of fears of continuing pseudomonas
infection that might have affected the transplanted
kidney. Even after transplantation, the patient con-
tinued to take one Percodan® per day together with
a large dose of the habituating drug codeine. Return
to analgesic abuse after transplantation has been re-
ported in a large number of patients with analgesic
nephropathy.
We are not told what the nephrectomy specimen
showed, but active recent necrotic papillary materi-
al may still have been present because of continued
analgesic intake. The final definitive proof of the di-
agnosis of analgesic nephropathy might be provided
by the nephrectomy specimens. Do we know what
was found on examination of the nephrectomy
specimen?
DR. VIvIAN Pir' (Patiwlogist, NEMCH): The
kidneys at the time of the bilateral nephrectomy
were atrophic and scarred, with the left weighing 78
g and the right, 74 g. The cortical surfaces were con-
tracted and granular with numerous cystically di-
lated tubules. Extensive bilateral papillary loss with
focal medullary calcification and occasional ossifi-
cation were present.
DR. P. KINcAID-SMI1H: In our experience, calci-
fication in these kidneys is almost invariable at au-
topsy and very frequently can be discerned radio-
logically. Most of our specimens, however, were
from patients who began dialysis after removal of
the kidneys. This patient underwent dialysis for 3
-i'---2 -.
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years prior to nephrectomy, and we cannot expect
to find in this specimen features that were there pri-
or to dialysis.
The lesion in analgesic nephropathy is very easily
recognized and quite distinct from all types of pye-
lonephritis. In the past, when patients took large
quantities of phenacetin, we found considerable
pigmentation in the papillae on autopsy. As the
years have gone by and phenacetin has virtually dis-
appeared from the market, the one thing that has
altered is the pigmentation of the papillae. Although
we still find necrotic papillae, they are not always
pigmented. The sequence of the injury proceeds
from necrosis of the papillae to the sloughing off of
the papillae into the ureters, which may obstruct the
kidneys. This is followed by shrinkage of the kidney
down to the cortex and enormous hypertrophy with
a white appearance in the columns of Bertin, giving
the kidneys an irregular shape, as was reported in
this patient. The characteristic radiologic lesions, of
course, are ring shadows formed by the necrotic pa-
pillae, with contrast medium encircling them. But
when the papillae are lost and only clubbing can be
seen, it is difficult to distinguish papillary necrosis
from reflux nephropathy. As I indicated earlier, the
papillae often remain attached, although they may
become calcified. Radiologic identification of the
disease depends on detachment of the papillae, of
course, but one cannot exclude the diagnosis just
because radiologic evidence of papillary necrosis is
not present.
DR. J. T. HARRINGT0N: I should like to add a few
comments regarding the patient. First, to the best of
our knowledge, he did stop taking phenacetin-con-
taming analgesics. He continued, however, to take
nonphenacetin-containing analgesic agents for pain
relief during the time between his initial presenta-
tion and the initiation of chronic dialysis. Second,
we thought that his persistent, recurrent infection,
not analgesic abuse, did more to damage his residu-
al kidney function than did anything else. Finally,
we have chosen to tolerate his taking one tablet of
Percodan® per day, which he has done since trans-
plantation, in the hope of preventing his ingestion of
larger amounts of other analgesics.
DR. P. KINCAID-SMITH: We once treated a man
whose course was similar to the patient presented
today. Our patient, who happened to be a doctor,
had been using analgesics for approximately the
same length of time as this patient. A peptic ulcer
was his first presenting sign some 15 years before he
came to us with renal symptoms. He died of a myo-
cardial infarction, not renal failure, but he had the
characteristic irregularly shaped kidneys with
marked hypertrophy in some areas and black-stain-
ing necrotic papillae. This doctor taught us a great
deal about his disease. On questioning, he revealed
that he actually was taking the analgesics for their
mood-altering effects and not for pain relief. At
first, he thought he was taking about 20 to 30 pills
per day, but when he actually counted, he docu-
mented taking 100 pills per day. I think this demon-
strates two important factors in the disease: (I) the
enormous resistance that one can develop to drugs
like salicylates, since this patient regularly took
what would be a fatal dose in one unaccustomed to
it; and (2) these patients do underestimate how much
they take. We gave our patient placebo tablets in
which various ingredients were missing. His re-
sponse confirmed my view that analgesic nephropa-
thy is predominantly caused by the habitual inges-
tion of analgesic compounds for their mood-altering
effects. The ingredients that he missed for the
mood-altering effects were the caffeine, which you
might expect, and the phenacetin; he did not really
care whether the drug contained aspirin. Thus, it
seems that there was no habituating effect of aspirin
in this man.
Another of our patients, a woman, well illustrates
many of the features of this disease. She first came
to us 20 years ago, and she stopped taking analge-
sics at that time. She died in the hospital just 2
months ago of incapacitating chronic congestive
heart failure from severe myocardial ischemia. Al-
though her course was marked by many complica-
tions, her first episode of hypertension occurred at
the commencement of the disease. Some months af-
ter therapy began, she returned with a non-
fuctioning left kidney and severe left loin pain. A
mass was found in the pelvis on radiologic examina-
tion; today we would immediately think of malig-
nancy in this context. An investigative operation
was performed by a urologist, who removed from
the kidney massive debris with a few little pig-
mented necrotic papillae caught up in it. This is the
sort of lesion that can develop particularly from re-
current episodes of pyelonephritis, which this pa-
tient had; staghorn calculi can develop very rapidly
in this setting with calcification and precipitation of
triple phosphates.
Even after her operation, this patient was not free
from trouble. After 3 years, the right kidney had not
altered much; it still had clubbed calyces with very
narrow cortex over them, but the left kidney had
ceased to function and a number of calculi were evi-
dent. In the next several years, the patient contin-
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ued to pass calculi, some of which were quite large
and resembled papillae. On decalcification and sec-
tioning, they contained necrotic papillae at the core,
which enabled us again to make a positive diagno-
sis. She continued in this fashion for more than a
decade, with her serum creatinine concentration re-
maining slightly below 3 mgldl. She then developed
increasingly severe hypertension and a decline in
renal function. She had lost the function of her left
kidney, as I mentioned, some years before because
of obstruction; she now developed severe stenosis
of the right renal artery. After surgical relief of the
stenosis, her renal function improved and her hy-
pertension disappeared. This patient is a prime ex-
ample of the severe atheroma that is common in an-
algesic nephropathy.
It is difficult in a group of patients with chronic
renal disease to document whether the incidence of
renal artery stenosis is higher than expected. We
compared 37 patients with analgesic nephropathy
and hypertension with 279 patients in the same age
group who had renal arteriograms that revealed no
analgesic nephropathy. The incidence of athero-
matous renal artery stenosis was much higher in the
patients with analgesic nephropathy than in the oth-
er patients (Table 1). Atheromatous renal artery ste-
nosis is predominantly a disease of men, whereas
fibromuscular renal artery stenosis is more common
in women.
Malignant hypertension is often a feature of anal-
gesic nephropathy. It frequently occurs early in the
course of the disease during a period of active
sloughing of renal papillae. Patients are often se-
verely salt depleted at this stage, and a paradoxical
relationship exists between salt and blood pressure
in this disease. For example, one woman who came
to us with malignant hypertension needed intra-
Table 1. Atheromatous lesions causing renal artery stenosis
(ARAS) in women
Hypertension Analgesic
only nephropathy
(No. of and hypertension
Age patients) ARAS (No. of patients) ARAS
10—19 9 0 0 0
20—29 57 4 (7%) I 0
30—39 86 7(14%) 3 2(66%)
40—49 77 14 (29%) 16 6 (37%)
50—59 39 25 (46%) 8 1(12%)
60—69 11 5 (42%) 9 5 (55%)
Total 279' 40" (14%) 37r 14' (37.8%)
Consecutive arteriograms in hypertensive women. Fibro-
muscular renal artery stenosis was evident in 16%.
"P <0.02
Consecutive arteriograms in women with hypertension and
analgesic nephropathy. Fibromuscular renal artery stenosis was
evident in 8%.
venous diazoxide to control her blood pressure at
first, but as her sodium depletion improved with salt
administration, and as her weight increased and her
serum creatinine concentration decreased, her hy-
pertension improved. After the initial treatment
with diazoxide, she needed only chlorothiazide and
reserpine to control her blood pressure; ultimately
her hypertension disappeared altogether. The rela-
tionship exists frequently enough in this group of
patients that we sometimes have found it very diffi-
cult to treat their hypertension unless we have com-
bined management of blood pressure with sodium
repletion.
Another striking feature in patients with analgesic
nephropathy is their premature aging. Wrinkling of
facial skin, aging of the body surface generally, very
early graying of hair, as well as early aging of arter-
ies is common.
A feature that we are beginning to encounter
more frequently in our patients is an associated uri-
nary tract malignancy, which was first described in
Sweden [26]. The lesion occurs even in patients
who have stopped taking analgesics and no longer
have active renal papillary necrosis. Again, it is dif-
ficult to document that these tumors occur more fre-
quently in patients with analgesic nephropathy, but
present evidence indicates that the incidence is
higher in these patients than in the general popu-
lation.
I think analgesic nephropathy probably first ap-
peared in this century. I say this because papillary
necrosis prior to the 1920s almost always was asso-
ciated with diabetes, and because the incidence of
papillary necrosis has increased significantly in var-
ious countries in recent years. Studies by Gloor
show that over a period of 20 years, the incidence of
renal papillary necrosis doubled in Switzerland [12].
Even in the United Kingdom, few instances of the
disease were noted early [27]; nonetheless a marked
increase did occur between 1961 and 1967. In addi-
tion, various studies in Australia reported an in-
creased incidence from 3.7% in 1962 [28] to 21% in
1973 [29]. Errors surely exist in these studies be-
cause such analyses are most accurate when per-
formed by a single pathologist. All of the studies
were carried out by different groups, and the vari-
ous pathologists may have used different diagnostic
criteria. I do not think there is any doubt that a very
big difference in prevalence of this disease exists
between Australia and, for example, countries such
as the United Kingdom and the United States.
The big question of course is why? In Australia at
least, we think that the use of modern advertising
techniques for over-the-counter analgesics was
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largely responsible for increased sales. This prac-
tice started shortly after World War I, and analgesic
sales rose tremendously in our country. According
to Australian Kidney Foundation Registry data,
24% of patients requiring dialysis and trans-
plantation between 1971 and 1979 had analgesic ne-
phropathy. The data show a striking difference in
distribution of the disease that correlates best with
total analgesic sales and sales of analgesic powders.
My colleagues and I have thought long and hard
about solutions to this problem. We have seen that
the withdrawal of phenacetin did not really help: the
actual number of analgesic abusers requiring dial-
ysis and transplantation continues to increase. At
present, we are trying to legislate restriction of cer-
tain over-the-counter compounds, most of them
containing either aspirin, salicylamide, and caf-
feine, or containing aspirin, paracetamol, and caf-
feine. Because we cannot determine whether any
one ingredient is responsible, we propose to restrict
the compounds that are universally abused. If the
stimulants are removed from the compounds, we
might see a reduction in misuse of the drugs. We
hope that these agents will be available only as
single ingredients in small packages in at least three
Australian states very soon.
Questions and Answers
DR. J. J. COHEN: For the sake of argument let me
adopt a position that a drug company might take.
The problem you have documented so well stems
from long-term abuse of the over-the-counter prep-
arations. No evidence indicates that any renal im-
pairment occurs from ordinary, episodic adminis-
tration of these pain-relieving agents. Moreover,
the availability both of single-agent and combina-
tion preparations allows people to choose the medi-
cation they prefer. Some people, for whatever rea-
son, are more satisfied with combination drugs. To
remove them from the market because a few people
abuse them would be doing a disservice to the ma-
jority who find them beneficial and unharmful at
lower doses. What then is the justification for
across-the-board restriction of their use, rather than
an alternative, such as mounting an educational
campaign to alert people to the dangers of abuse?
DR. P. KINCAID-SMITH: Our educational cam-
paigns of nearly 20 years do not seem to have had
any impact. Abuse occurs almost entirely with com-
bination preparations. Occasionally we treat a pa-
tient who has abused aspirin alone; the literature
describes only 10 patients who have abused aspirin
alone and developed the syndrome. I think we have
treated 2 patients who have abused paracetamol
alone and developed the lesion. The vast majority
of patients take a combination drug, as did the pa-
tient discussed today. And in most countries where
analgesic nephropathy is a serious problem, combi-
nation preparations with mood-altering effects are
the agents most widely abused. Thus, we do not be-
lieve that elminating analgesic compounds is a hard-
ship to ordinary people who want relief from head-
aches or toothaches. We propose to let them buy a
small, single-ingredient analgesic, which is all they
need. One of the problems in Australia is that these
drugs are sold by the gross in our supermarkets. Of
course, the drug companies argue that the majority
of the community should not be penalized for some-
thing that affects a small percentage of people. But
in Australia this is a serious problem: analgesic ne-
phropathy is present at 20% of all autopsies; it ac-
counts for 20% of people who come into dialysis or
transplant programs; and for each individual who
starts dialysis, our studies show that at least 100
others in the community are suffering from serious
chronic complaints such as hypertension, renal cal-
culi, and renal infection.
We think the problem is serious enough to require
governmental intervention. We believe that restric-
tion of the amount in each childproof package
would automatically increase the cost and minimize
the possibility that people will take a combination of
drugs to obtain the mood-altering effects. We have
considered the problem for a long time, and we
thought we had it solved when phenacetin was re-
moved from the mixtures; but that has not been the
answer. After years of discussion at the Australian
Kidney Foundation and elsewhere, agreement has
been reached that restriction is the course most
likely to help, but time will tell.
DR. J. J. COHEN: Not to belabor the point, but we
could argue by analogy that alcohol is even a great-
er danger to society. Yet we have not had much
luck in prohibiting its sale.
DR. P. KINCAID-SMITH: Tobacco and alcoholic
beverages are very good examples of agents that
produce moral problems in the community. My de-
fense would be that I do not have to dialyze people
who have abused alcohol. This is a very personal
view, but in fact, 20% of Australia's dialysis costs
are attributable to drug abuse; that is $15,000 per
patient per year. After all, analgesics are medicines
and they would not pass the present animal testing
requirements if they were introduced now. Aspirin
is a good drug, but if tested under today's standards
it would be available only with stringent criteria for
its use. I think there is a difference between alcohol
and tobacco, and medicines. We are not allowed to
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use medicines that have far lesser adverse effects
than the agents we are discussing.
DR. J. T. HARRINGTON: You have said that cer-
tain combinations of analgesics are more likely to
cause renal lesions than are others. The experience
in patients with chronic rheumatoid arthritis who
lake aspirin in very large quantities for many years
argues against aspirin alone as an important agent in
producing renal damage. Although histologic
changes can occur in these patients, they have a
very low incidence of end-stage renal disease from
papillary necrosis. Second, the experience in Cana-
da with phenacetin is apparently different than
yours in Australia; Gault's studies claim that the in-
cidence of papillary necrosis has decreased since
the removal of phenacetin sometime in the early
1970s [30]. That seems at variance with the findings
in Australia.
DR. P. KINCAID-SMITH: Yes, it is at variance to
some extent. There does seem to have been a de-
dine in Canada but certainly not in Australia.
The low incidence of papillary necrosis in rheu-
matoid arthritis is, I think, related partly to dosage.
We used to be able to document how much of the
drug people were taking much better than we can
today. As I mentioned earlier, people take larger
quantities than they think. In rheumatoid arthritis,
it is often a struggle to get the patient to take 20
aspirin tablets a day. Such patients do develop renal
lesions, but they very rarely present with significant
nephropathy; those that do almost always have
abused mixtures of drugs in big doses. So I agree
with you. I am not by any means saying that aspirin
alone is responsible. We were very surprised indeed
when our rats developed lesions when given aspirin
and not when given phenacetin. We expected to in-
duce lesions with a combination preparation be-
cause we were using the same model that Abrahams
and Levin had reported with a combination [31].
We were again surprised when we continued to see
the same syndrome even after phenacetin had been
removed from one of the two most widely used
agents and replaced with salicylamide, which is to-
tally unrelated chemically. One is forced to con-
clude that no single ingredient is responsible. To re-
turn to the experimental animal data, which is after
all how we test all drugs, I think there is reasonably
good evidence for some common pathway, perhaps
prostaglandin inhibition, that all of these agents
share.
DR. DAVID BUSHINSKY (Renal Fellow,
NEMCH): In view of the new, potent, nonsteroidal
antiinflammatory agents, which are also prosta-
glandin inhibitors, do you foresee another class of
drugs causing papillary necrosis or analgesic ne-
phropathy?
DR. P. KINCAID-SMITH: We have not tested
them. For a number of years, we had a model set up
for testing drugs, but we have not examined the
newer ones. The process is very time consuming.
Theoretically, that should be so. I have no doubt
that the drug companies have some data on papil-
lary necrosis with various drugs, but I have not had
access to it.
DR. NIc0LA0s E. MADIAS (Renal Service,
NEMCH): Your data describe patients with impres-
sively high serum creatinine concentrations that re-
turned to normal after some time. How much of this
improvement in renal function was due to relief of
acute obstructive disease?
DR. P. KINCAID-SMITH: The serum creatinine
concentration of patients with obstruction de-
creased dramatically—a straight decline graph-
ically—with relief of obstruction. I doubt that the
long, continued improvement we saw over years
was related to obstruction. In most patients who
present initially with high serum creatinine concen-
trations, some degree of active papillary necrosis is
present and obstruction cannot be excluded. In our
group of 25 patients, we could document obstruc-
tion of at least one kidney in 8 or 10 patients. Thus,
obstruction alone was not responsible for the in-
creased creatinine levels; other factors such as
acute infection contributed to the rise. A factor that
may be important in determining how much im-
provement occurs is the tendency for papillae to ad-
here far more readily with the aspirin-salicylamide-
caffeine preparation than with the APC combina-
tions, whether they contain phenacetin or para-
cetamol. Patients who slough papillae seem to re-
cover much better than do those whose papillae ad-
here. I do not think therefore that obstruction was
by any means the only factor in those long, contin-
ued improvements; but it was a factor in some of
the patients. It is very difficult to separate them
completely. It is not as simple as relieving obstruc-
tive stones.
DR. AARON SPITAL (Renal Fellow, Rhode Island
Hospital): In view of the availability of the combi-
nation preparations in the United States, do you
think there is a real difference in the incidence of
analgesic nephropathy between Australia and the
United States, or do you think we may have a diag-
nostic problem and the disease simply is not being
identified here?
DR. P. KINCAID-SMITH: A number of our post-
doctoral fellows have studied in the United States
and report identifying only one or two instances of
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papillary necrosis from analgesic abuse during their
time here. Clearly, they have seen the disease fre-
quently in Australia and therefore should have no
problem diagnosing it. So I think there is a real dif-
ference. For similar reasons, I am convinced of a
real difference in incidence between the United
Kingdom and Australia. Before I went to Australia,
I was with Hammersmith Hospital in London for 6
years and participated in virtually every autopsy
performed there; during that period I saw only two
instances of what I called an unusual form of papil-
lary necrosis, unlike the diabetic form. In Australia,
this unusual" form of the disease was an almost
daily occurrence in the autopsy room. I do not
know the reason for the difference in the incidence,
and only suggest that the tremendous advertising
campaigns in Australia are responsible for the prev-
alence of the disease. Much of the advertising now
has been stopped, but the community habit is well
established. There is an extremely high incidence of
the disease in one area of Glasgow, where a powder
containing a large amount of caffeine is popular; our
mixtures contain this powder also. Murray has sug-
gested that high doses of caffeine predispose to
abuse. Murray and Goldberg suggested that you
have a much higher incidence of the disease in the
United States than you think [8]. I believe approxi-
mately 7% of patients entering your dialysis pro-
grams have this disease. So it may indeed be more
prevalent than you think.
DR. J. T. HARRINGTON: I believe tumors of the
renal pelvis occur in approximately 8% to 10% of
patients with analgesic nephropathy. How would
you make that diagnosis in a patient who has pro-
teinuria, hematuria, abnormal renal function, and
papillary necrosis without performing a series of
retrograde urographic procedures?
DR. P. KINCAID-SMITH: It is not easy at all. We
are always worried when microscopic hematuria is
present because it may indicate glomerular damage.
We have a technique, which we are just perfecting.
for recognizing the difference between red cells that
come from the glomerulus and red cells that come
from lower in the kidney [33]. We have not seen
many tumors, and in those few patients in whom we
have diagnosed tumors, I cannot tell you whether we
have actually made the diagnosis on the basis of this
technique. It is a difficult differential diagnosis; in
fact, the disease is more commonly diagnosed at au-
topsy than in any other manner.
DR. J. T. HARRINGTON: Given the difficulty in
making this diagnosis, would you remove the kid-
neys because of this predilection for tumors in a pa-
tient who is going to receive a kidney transplant?
This may be especially worrisome because immu
nosuppressive agents are thought to increase the
likelihood of epithelial tumors.
DR. P. KINcAID-SslirH: We have not done this
recently. We only have removed the kidneys it
there was a problem with infection. The answer to
your question may become apparent if the many pa-
tients in Australia who have had renal transplants
because of analgesic nephropathy subsequently de-
velop tumors, but it has not happened yet.
DR. J. T. HARRINGTON: Could you give us a pre-
view of your techniques for distinguishing between
red cells that come from the glomeruli and those
that come from other areas of the kidney?
DR. P. KINCAID-SMITH: It seems that red cells
that come from glomeruli have definite extrusive
features, and those that come from the bladder or
pelvis look like ordinary red cells.
DR. J. T. HARRINGTON: Are the cells examined
under light microscopy?
DR. P. KINCAID-SMITH: Yes. We have used elec-
tron microscopy but it has not been terribly inform-
ative. Using light microscopy one can quite accu-
rately distinguish between glomerular red cells and
others.
DR. MARTIN GELMAN (Renal Service, St. Eliza-
bet/i's Hospital): Do we know enough about the ef-
fects of the combination analgesics to determine
which ones seem to be the worst offenders?
DR. P. KINCAID-SMITH: We do not know enough
about the combinations. Our studies in Australia in-
dicate that about one-third of patients took various
agents, but about one-third took either the phenace-
tin-containing analgesic or the salicylamide-con-
taming analgesic.
DR. N. E. MADIAS: Did you exclude patients with
diabetes from your series? Does the combination of
diabetes and analgesic abuse produce a more devas-
tating degree of papillary necrosis?
DR. P. KINCAID-SMITH: We did exclude patients
with diabetes from the studies that I have men-
tioned. We see a few people with diabetes who take
analgesics and develop papillary necrosis, but then
we see a few diabetic patients who do not take anal-
gesics and who develop papillary necrosis. I think
the combination is worse, but it is not devastating.
Diabetes is certainly a much rarer cause of papillary
necrosis in Australia than is analgesic abuse.
DR. J. J. COHEN: You emphasized the problem of
controlling infection in patients such as the one un-
der discussion today. Kass recently has reaffirmed
his long-standing advocacy of mandelamine or hip-
puric acid for long-term suppression and eradica-
tion of infection in patients who have highly resis-
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tant organisms [34]. Have you had experience with
this regimen?
DR. P. KINCAID-SMITH: Yes, but I think that in
this patient we would have had difficulty getting
adequate concentrations of these agents into the
urine. The serum creatinine concentration was al-
ways higher than about 4 mgldl. I think the trouble
with mandelamine is that it works in the bladder but
not in the kidney. We have used it for long-term
prophylaxis in patients in whom infection has been
eradicated rather than as the initial treatment for in-
fection. I think pseudomonas is one of the most dif-
ficult organisms to eradicate, and the only drug
combination with which we have had success has
been the oxytetracycline/cotri moxazole combina-
tion.
Reprint requests to Dr. P. Kincaid-Smith, Depart,nent of
Nephrologv, Royal Melbourne Hospital. Victoria, Australia.
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